Genetic Predictors of Ibrutinib-Related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia.

Issam S Hamadeh Jai Narendra Patel Ryan Jacobs Hang Zeng Jiaxian He Bei Hu Tamara Kay Moyo Amy Soni Steven I Park Ed Copelan Belinda Avalos Alicia Hamilton Nury Steuerwald Nilanjan Ghosh

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Our findings suggest possible genetic determinants of ibrutinib-related CVSEs in CLL. If replicated in a larger study, pre-treatment pharmacogenetic testing for GATA4 and KCNQ1 polymorphisms may be a useful clinical tool for personalizing treatment selection for CLL and/or instituting early risk-mitigation strategies.

Keyphrases

chronic lymphocytic leukemia
genome wide
transcription factor
climate change
combination therapy
dna methylation
replacement therapy
drug induced